(Reuters) -German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent dispute related to mRNA-based COVID-19 vaccines, CureVac said.

As part of the settlement, CureVac and GSK will receive a combined payment of $740 million and single-digit royalties on sales of COVID-19 vaccines in the U.S. going forward.

CureVac will also grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import and sell mRNA-based COVID-19 and influenza products in the U.S.

The settlement comes after BioNTech agreed to acquire its domestic peer CureVac in a $1.25 billion all-stock deal in June.

Three years ago, CureVac had filed a patent lawsuit against BioNTech over its use of mRNA technology, seeking fair compensation from the compa

See Full Page